Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Eye Movements and Visuo-spatial Perception

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03112408
Recruitment Status : Completed
First Posted : April 13, 2017
Last Update Posted : April 21, 2022
Sponsor:
Information provided by (Responsible Party):
Hospices Civils de Lyon

Tracking Information
First Submitted Date  ICMJE March 29, 2017
First Posted Date  ICMJE April 13, 2017
Last Update Posted Date April 21, 2022
Actual Study Start Date  ICMJE September 26, 2018
Actual Primary Completion Date October 2, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 7, 2017)
Saccadic adaptation efficiency [ Time Frame: At time of each experimental session, up to 2 months, since first experimental visit until last visit ]
〖Adaptation〗_rate= (〖Amplitude 〗_post-〖Amplitude 〗_pre)/〖Amplitude 〗_pre
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 7, 2017)
  • Evolution of localization-task performances [ Time Frame: At time of each experimental session, up to 2 months, since first experimental visit until last visit ]
    〖Improvement〗_performances= (〖Mislocalization 〗_post-〖Mislocalization 〗_pre)/〖Mislocalization 〗_pre
  • Evolution of attentional performances assessed by neuropsychological tests of neglect [ Time Frame: At time of each experimental session, up to 2 months, since first experimental visit until last visit ]
    〖Improvement〗_performances= (〖Score 〗_post-〖Score〗_pre)/〖Score〗_pre
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Eye Movements and Visuo-spatial Perception
Official Title  ICMJE Coupling Between Adaptation of Saccadic Eye Movements and Visuo-spatial Perception and Attention Processes: a Behavioural Study in Humans.
Brief Summary This research aims to highlight the key roles of the cerebellar and cortical fronto-parietal networks in the coupling of eye movements with visual perception and visuo-spatial attention.
Detailed Description

The first axe of this research focuses on the role of the cerebellum which has a major contribution to sensorimotor adaptation and more precisely in saccadic adaptation but the nature of this contribution is still debated. A classical assumption stipulates cerebellum has an exclusive action on saccadic burst generator in the brainstem whereas recent data increasingly support the view that cerebellum could also modulates cerebral cortex through a cerebello-thalamo-cortical pathway. On the other hand, several studies have shown that modification of saccade amplitude by saccadic adaptation leads to a distortion of the visual localization of briefly flashed spatial probes but no study to date has tested, the contribution of the cerebellum in these adaptation-induced mislocalizations. The main objective of this axe is to define the role of the cerebellum not only in saccadic adaptation, but also in mislocalizations which occur after adaptation. Moreover, in testing this assumption, arguments in favour -or in disfavor- of the action of the cerebellum on cortical stages dedicated to visuo-spatial perceptual processing will be provided. Besides, variability of cerebellar lesion (or cerebellar dysfunction) location in patients can lead to different pattern in saccadic adaptation and localization task performances. Identification of dissociations between these two abilities in some patients will define more precisely the role of the cerebellum in the coupling between saccadic adaptation and visuo spatial perception as an oculomotor plasticity territory and / or as a territory underlying the error signal coding generating this type of plasticity.

This second axe of this research aims to apply basic findings in healthy subject on the coupling between oculomotor plasticity and spatial attention to patients with parietal lesion, in order to evaluate a rehabilitation procedure for neglect patients. Habchi and colleagues showed that the adaptation of reactive saccades in the left hemifield has a boosting effect on attentional performance in the same hemifield. The coupling between these two mechanisms highlighted in healthy subjects can be used as fundamentals in the elaboration of a rehabilitation procedure for attentional disorders in the neglect syndrome. This syndrome is mainly observed after cerebral lesions in the right hemisphere, and is characterized by very disabling cognitive disorders such as an alteration of the spatial representation of left hemi-space and/or left hemi-body. stimulation of sensorimotor plasticity thanks to prismatic adaptation could be used as a rehabilitation procedure for this syndrome. Being another efficient way to stimulate sensorimotor plasticity, the equip believe that saccadic adaptation can also be used as a rehabilitation procedure for neglect patients. Moreover, due to its tight coupling with visual attention, the benefits of saccadic adaptation could be even stronger and longer lasting than the visuo-manual plasticity induced by prismatic adaptation.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Condition  ICMJE Cerebellum Disease
Intervention  ICMJE
  • Behavioral: Forward adaptation of reactive saccades
    Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
  • Behavioral: Backward adaptation of reactive saccades
    Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
  • Behavioral: Execution of reactive saccades
    Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
  • Behavioral: Generation of reactive saccades
    Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
Study Arms  ICMJE
  • Experimental: FORWARD (Axe 1)
    Intervention: Behavioral: Forward adaptation of reactive saccades
  • Experimental: BACKWARD (Axe 1)
    Intervention: Behavioral: Backward adaptation of reactive saccades
  • Experimental: CONTROL (Axe 1)
    Intervention: Behavioral: Execution of reactive saccades
  • Experimental: ADAPTATION (Axe 2)
    Intervention: Behavioral: Backward adaptation of reactive saccades
  • Experimental: CONTROL (Axe 2)
    Intervention: Behavioral: Generation of reactive saccades
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 20, 2022)
24
Original Estimated Enrollment  ICMJE
 (submitted: April 7, 2017)
75
Actual Study Completion Date  ICMJE October 2, 2020
Actual Primary Completion Date October 2, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Age : from 18 to 80 ans included
  • Visual acuity monocularly at distance and near corrected : > 5/10
  • Possible understanding of experimental guidelines
  • Possible respect for sustained seated position
  • Subject covered by social security
  • Agreement of the subject

Inclusion Criteria, specific to Axe 1:

  • Cerebellar patients - Cerebellar degenerative disease (group A) or stroke (group B, délai depuis l'AVC : delay from the stroke : at least 1 month)

    • Scanner or MRI showing diffuse atrophy (group A) or focal cerebellar lesion (group B)
  • Healthy subjects

    • Absence of known ophtalmological or neurological pathology

Inclusion Criteria, specific to Axe 2:

  • Stroke patients - ischemic or hemorrhagic stroke

    • Encephalic MRI or CT scan showing an unique lesion
    • Minimal delay of one year after the stroke

Exclusion Criteria:

  • Visual acuity monocularly < 5/10
  • Language disorder restricting oral and reading comprehension of the study
  • Severe disability limiting the maintenance of sitting position and concentration capacities for a period of 30 minutes consecutive
  • Poor French language skills
  • Non-stabilized medical condition
  • Psychotropic medication intake
  • Pregnant and / or nursing women
  • Subject under guardianship or curatorship
  • Subject frequently in healthcare or social care for purposes other than research
  • Subject deprived of liberty by a judicial or administrative decision

Exclusion Criteria, specific to Axe 1:

• Cerebellar patients

- Disorders prohibiting the correct performance of the task (tremor, ocular instability)

Exclusion Criteria, specific to Axe 2:

• Stroke patients

  • Hemianopsia homonima lateral
  • Neurological degenerative disease
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 80 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03112408
Other Study ID Numbers  ICMJE 69HCL17_0109
2017-A00942-51 ( Other Identifier: ID-RCB )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Hospices Civils de Lyon
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Hospices Civils de Lyon
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Caroline Tilikete, MD Hospices Civils de Lyon
PRS Account Hospices Civils de Lyon
Verification Date April 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP